BioSpace News Archive

Business

TCR2 Therapeutics Leases Manufacturing Space in Maryland, Autolus Backs Out of U.S. Expansion

After Autolus Therapeutics’ backed out of its plan to establish a manufacturing center in Rockville, Maryland, Massachusetts-based TCR2 Therapeutics has stepped up to the plate to build an 85,000 square-foot cell therapy manufacturing facility in Rockville.

March 30, 2021
·
3 min read
·
Alex Keown
2021 Biopharma Update on the Novel Coronavirus: March 30

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2021.

March 30, 2021
·
3 min read
·
BioSpace Editorial Staff
Genetown

Omega Raises $126 Million to Unlock Potential of Epigenomic Controller Candidate

Omega Therapeutics secured $126 million in a Series C financing round that will be used to advance the company’s lead epigenomic controller candidate, OTX-2002, a potential treatment for hepatocellular carcinoma, as well as other next-generation pipeline assets.

March 30, 2021
·
2 min read
·
Alex Keown
Drug Development

Wave to Discontinue Lead Huntington’s Programs After Disappointing Clinical Data

Disappointing data from two Phase Ib/IIa trials for both lead Huntington’s disease antisense candidates have pushed Wave Life Sciences to shelve the assets and focus on its next generation of therapies.

March 30, 2021
·
2 min read
·
Mark Zipkin
Deals

Antitrust Concerns Hinder Second Illumina Acquisition, FTC Raises Concern Over $8 Billion Deal for Grail

Illumina plans to continue to pursue its acquisition of Grail Inc. despite the objection of the U.S. Federal Trade Commission.

March 30, 2021
·
3 min read
·
Alex Keown
Drug Development

Merck KGaA’s ATR Inhibitor Shows Promise in Both Cancer and COVID-19

A research collaboration among UCLA investigators and Merck KGaA, has pointed to the drug as showing promise for COVID-19. It is also being touted for its unusually broad effect in treating a range of cancers.

March 30, 2021
·
3 min read
·
Mark Terry
Drug Development

ALS Patients Fight for the Right to Try and Patient-Centric Trial Design

Lisa Stockman Mauriello was diagnosed with ALS in January and is seeking access to Biogen’s tofersen (BIIB067) through the Right to Try Act. Her case has reinvigorated the ALS community and its fight for expanded access to investigational therapies for this cruel, always fatal disease.

March 30, 2021
·
7 min read
·
Heather McKenzie
Business

Money on the Move: March 24-30

Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week.

March 30, 2021
·
5 min read
·
Kate Goodwin
Business

Takeda Pairs Up With BridGene to Solve “Undruggable” Neurodegenerative Diseases

The companies will harness BridGene’s IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates.

March 30, 2021
·
2 min read
·
Alex Keown
Policy

Merck’s Busy Day: FDA Rejection, EU Recommendation and a Spinoff Sale

Merck is having a very busy week. Here’s today’s news.

March 30, 2021
·
3 min read
·
Mark Terry